Usher researchers lead on €29 million grant to assess risk posed by deadly lung infections
Professor Harish Nair is leading a European consortium to understand and assess the problem of Respiratory Syncytial Virus (RSV) across Europe.
Experts in the Usher Institute are leading a €29 million research consortium to investigate serious lung infections that particularly affect babies and older adults.
The research aims to improve the management of Respiratory Syncytial Virus (RSV) infections.
Respiratory Syncytial Virus (RSV)
RSV infections are estimated to affect more than 30 million children under five each year. The virus also affects older people and those with weakened immune systems, including cancer patients and people with chronic lung diseases such as emphysema.
There are no specific treatments for RSV and there is no vaccine. Current therapies are focused on alleviating the symptoms of the infection.
RSV infection causes breathing difficulties and wheezing and can lead to severe respiratory illnesses such as bronchiolitis or pneumonia.
The virus can be the most common single reason for children being admitted to hospital over the winter months. In older adults, the infections may cause as many severe illnesses, hospitalisations and deaths as influenza.
Led by Professor Harish Nair at the University of Edinburgh, the RSV Consortium in Europe (RESCEU) aims to make a fundamental difference to the understanding and management of RSV. International teams will work to assess the full scale of the problem in Europe, which is currently unknown.
Investigators from 18 universities, public health institutes and pharmaceutical companies will gather robust statistics on the number of RSV cases across Europe each year.
Researchers will also assess the economic impact of the disease and the burden it places on healthcare systems. Armed with this information, the group will put together best practice guidelines to improve the way RSV-associated disease is monitored across Europe and to advise future vaccination programmes.
The consortium aims to ensure that future decisions on RSV prevention and treatment policies can be based on good evidence and made without undue delay.
The group also aims to set up a framework to conduct Europe-wide trials of new medicines and vaccines to improve treatment, and even prevention, of the disease. They will collect and analyse patient samples to identify biological markers associated with severe RSV infections. Such markers could help to improve diagnosis and assessment of the severity of disease. They could also aid the development of treatments and vaccines.
Funding and future
Funding has been received from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 116019. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
RESCEU was born out of an existing research collaboration called the Respiratory Syncytial Virus Network (ReSViNET) which aims to improve understanding of this virus, and to develop safe and effective preventive treatment and prevention strategies.
We are at an opportune time to step up efforts to prevent RSV infection in children and elderly populations. With more than 65 candidate vaccines in clinical development, it is likely that an RSV vaccine will be available in the next five to seven years. Moreover, a range of treatments for RSV are also being developed. Our findings will provide better evidence to understand how these interventions should be best introduced, not only in Europe but also the rest of the world.”
The collaboration includes the Universities of Edinburgh, Oxford and Imperial College London from the UK. Also taking part are teams from the University Medical Center Utrecht, University Medical Center Groningen and the National Institute for Public Health & The Environment in the Netherlands, the University of Antwerp in Belgium, the Galician Health Service SERGAS in Spain, the Hospital District of Southwest Finland, Statens Serum Institut in Denmark and the Paediatric European Network for Treatment of AIDS Foundation.
Six companies are participating in the project – AstraZeneca, Pfizer, GlaxoSmithKline Biologicals, Sanofi Pasteur, Janssen Pharmaceutica and Novavax – together with Synapse Research Management Partners.
A further 43 research and public health institutions, patient societies and clinical societies from Europe and rest of the world are also affiliated to the project.